Clinical Trials
22 trialsNCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT06941688 2025-04-24
Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma
Seoul National University Hospital
Phase 2 Terminated
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT05105412 2024-07-08
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
National Health Research Institutes, Taiwan
Phase 1/2 Terminated
NCT01769222 2024-01-24
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
Phase 1 Terminated
NCT02535247 2022-07-08
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT01678443 2021-04-02
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT03601819 2021-01-22
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT01643603 2020-12-17
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT01609816 2020-03-16
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01408043 2019-06-14
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase NA Terminated
NCT01419795 2017-07-27
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT01841021 2017-01-19
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00996359 2013-09-17
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT00514722 2013-08-14
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
University of California, San Francisco
Phase NA Terminated
NCT01036399 2012-08-27
Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients
University of Bologna
Phase 2 Terminated
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00704691 2012-04-20
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
University of Alabama at Birmingham
Phase EARLY_PHASE1 Terminated
NCT01116154 2010-12-09
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Terminated
NCT00441025 2009-06-25
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
Mahidol University
Phase 2 Terminated